Research & Development Pipeline

Biogen Idec Hemophilia is researching innovative, fully recombinant clotting factor replacement products to determine if there is potential to provide prolonged protection from bleeding for people with hemophilia A or hemophilia B.

*We have concluded late-stage clinical trials (Phase III) that evaluated long-lasting recombinant factor VIII (rFVIIIFc) and long-lasting recombinant factor IX (rFIXFc). We anticipate submitting Biologics License Applications (BLA) to the U.S. Food and Drug Administration (FDA) in the first half of 2013.